Development of the medical marijuana industry in Poland 2026 – report

Poland entered the year 2026 as one of the fastest-growing medical marijuana markets in the European Union. The number of prescriptions issued exceeded 1.4 million, and the estimated patient base is over 300,000 people (Chief Pharmaceutical Inspectorate, 2025). This is an increase of three orders of magnitude compared to 2018, when only 1,900 prescriptions were filled in pharmacies.

Despite the dynamic demand, domestic production remains practically zero. 100% of pharmaceutical cannabis comes from imports, mainly from Canada, Germany, and Portugal (Polish Society of Cannabis Medicine, 2025). This paradox, that is, rising demand amid a lack of domestic supply, defines the condition of the Polish hemp industry in 2026 and opens the door for regulatory changes.

In this report, we present the state of the medical marijuana industry in Poland at the end of the first quarter of 2026. We discuss the regulations of the Ministry of Health and GIF, patient data, the distribution chain, telemedicine, imports, and forecasts until 2030. All figures come from public sources and industry organizations.

KEY INFORMATION
– Medical marijuana has been legal in Poland since November 1, 2017, based on the amendment Dz.U. 2017 item 1458 (ISAP, 2017).
– In 2025, over 1.4 million prescriptions for hemp flower were filled, about 300 thousand patients (Pharmacy Market, 2025).
– 100% of the raw material comes from imports, mainly from Canada (55%) and Germany (18%) (Polish Society of Cannabis Medicine, 2025).
– The market will grow from 110 million euros in 2025 to an estimated 280-340 million euros in 2030 (Statista, 2025).
– Only about 4,200 doctors in Poland regularly issue prescriptions with "Rp.w." (Supreme Medical Chamber, 2025).
– The average price of flower in a pharmacy is 55-75 PLN per gram, with a monthly therapy cost of 600-1500 PLN.

What is the legal status of medical marijuana in Poland in 2026?

Medical marijuana has been legal since November 1, 2017, based on the amendment to the Act on Counteracting Drug Addiction (Dz.U. 2017 poz. 1458). In 2026, additional regulations from the Ministry of Health from July 2025 and January 2026 are in effect, which tighten the rules for issuing e-prescriptions and introduce a limit of 60 g per single prescription.

The doctor issues a prescription with the annotation „Rp.w.” (prescription for a specific product) for a specific preparation registered in Poland. In 2025, there were 47 registered strains of cannabis flower from 11 importers available in pharmacies (Ministry of Health, 2025). The patient fills the prescription at a pharmacy that must have a GIF permit for the trade of narcotic substances.

Importantly, Polish law does not define a closed list of indications. The decision to prescribe medical marijuana is up to the doctor, who assesses the individual situation of the patient. The most common indications include chronic pain resistant to treatment, drug-resistant epilepsy, spasticity in multiple sclerosis, nausea after chemotherapy, and Tourette's syndrome.

What changed with the regulation from July 2025?

The Ministry of Health regulation from July 1, 2025, introduced three fundamental changes. First, the limit for the amount of flower prescribed at one time is 60 g (previously there was no formal limit). Second, the doctor must conduct a patient examination at least once every 6 months. Third, every prescription must be issued in the Medical Information System (SIM).

The aim of the changes was to combat the practice of mass prescriptions issued by a few telemedicine platforms. According to a report by the CBA from 2024, about 8% of prescriptions raised quality concerns (CBA, 2024). The new rules aim to improve oversight of the chain of diagnosis, prescription, and dispensing.

What changed with the regulation from January 2026?

Starting from January 1, 2026, every e-prescription for narcotic drugs issued via teleconsultation requires an audiovisual interview (video call). The doctor must record the number and duration of the visit in the SIM. This is a response to the practice of „prescriptions in 5 minutes” and aims to strengthen clinical responsibility for the prescribed preparation.

Additionally, the Ministry of Health announced consultations in February 2026 regarding the reimbursement of medical marijuana for patients with drug-resistant epilepsy and multiple sclerosis. A decision is expected in the second half of 2026. This could be a milestone for the industry and for the patients themselves.

Poland legalized medical marijuana on November 1, 2017, and in 2026, additional regulations from the Ministry of Health are in effect, introducing a limit of 60 g per prescription and the requirement for an audiovisual interview during teleconsultations (Ministry of Health, 2026). The changes aim to improve patient safety and reduce pathologies in the telemedicine market.

How many patients use medical marijuana in Poland?

The number of prescriptions for hemp flower exceeded 1.4 million in 2025, corresponding to 300-340 thousand unique patients (Rynek Aptek, 2025). This is an increase of about 65% year-on-year. In comparison, in 2018, only 1,900 prescriptions were filled in Poland, and in 2020, about 28,000.

The profile of a typical patient is a person aged 35-65, more often male (54%), diagnosed with pain syndromes, neurological or oncological conditions (Polish Society of Cannabis Medicine, 2025). The average monthly consumption per patient is 15-25 g of flower, which corresponds to an expenditure of 800-1700 PLN per month.

A significant portion of patients use medical marijuana instead of or alongside opioids. In a survey by the Polish Society of Cannabis Medicine from 2024, 41% of respondents reported reducing their morphine or oxycodone dosage after incorporating cannabis into their therapy. This corresponds with international data (EMCDDA, 2024).

Dynamics of prescription growth 2018-2025

The growth curve is almost exponential. In 2018, there were 1,900 prescriptions, in 2019, 6,200, in 2020, 28,000, in 2021 about 110,000, in 2022 about 320,000, in 2023, 580,000, in 2024, 870,000, and in 2025, over 1,400,000. Poland is currently the second-largest medical marijuana market in the EU by volume after Germany (Statista, 2025).

What are the reasons for the growth? First, the development of telemedicine platforms facilitating access to prescriptions. Second, the growing awareness of patients and families of people with chronic diseases. Third, the emergence of a greater number of registered strains of flower (47 in 2025 compared to 8 in 2020).

Patient demographics in 2026

According to a survey by the Polish Society of Cannabis Medicine from March 2026, the age structure of patients is as follows: 18-34 years (22%), 35-49 years (31%), 50-64 years (28%), 65+ (19%). The fastest-growing segment is 50+, which constituted only 31% of the base in 2022 and now accounts for 47%.

Geographically, the largest concentration of patients occurs in the Mazowieckie (18% of all prescriptions), Silesian (12%), Greater Poland (10%), and Lesser Poland (9%) voivodeships. The least representation is in the Lublin and Świętokrzyskie voivodeships. The difference is partly due to the availability of doctors specializing in cannabis therapy.

In 2025, over 1.4 million prescriptions for medical marijuana were filled in Polish pharmacies, corresponding to a base of 300-340 thousand unique patients (Rynek Aptek, 2025). This is an increase of three orders of magnitude compared to 2018, when only 1,900 prescriptions were filled. Poland is now the second market in the EU by volume after Germany.

Where does Poland import medical marijuana from?

100% of the pharmaceutical raw material used in Poland in 2026 comes from imports, as domestic production is in the pilot phase. The annual import volume in 2025 was about 22 tons (Polish Society of Cannabis Medicine, 2025), compared to an estimated 14 tons in 2024 and 7 tons in 2022. The increase in imports reflects the rise in domestic demand.

The largest suppliers are Canada (about 55% of the volume), Germany (18%), Portugal (12%), North Macedonia (8%), and Australia (4%). The rest comes from the Czech Republic, Denmark, the Netherlands, and Lesotho. Why does Canada dominate? This country legalized medical production as early as 2001 and has the most developed GMP cultivation system globally (Health Canada, 2024).

Importers operating in Poland must have a GIF permit for the trade of precursors and narcotic substances. In 2025, 11 entities held such permits. The supply chain includes a foreign grower, importer, pharmaceutical wholesaler, and pharmacy. Each stage requires GMP documentation and quality control.

Why does Canada dominate the Polish market?

First, Canada has 25 years of experience in the commercial production of medical marijuana. Second, Canadian producers meet EU-GMP requirements, that is, European pharmaceutical standards. Third, long-term contracts with Polish importers ensure supply stability, and transportation costs are offset by high crop yields.

However, logistical challenges are emerging. The time from order to dispensing at the pharmacy averages 6-12 weeks. This is long, considering that a patient with chronic pain needs continuity of therapy. Therefore, there are often interruptions in the availability of specific strains, which frustrates both patients and doctors.

What does domestic production look like in 2026?

Domestic production of medical marijuana in Poland in 2026 is practically zero on a commercial scale. The Institute of Natural Fibers and Medicinal Plants in Poznań is conducting a pilot plantation of about 0.3 ha under GACP standards. The first harvest is planned for the second quarter of 2026, but the volume will not cover even 1% of the annual demand.

Barriers to the development of domestic production include high investment costs (40-80 million PLN for a GMP facility), lack of dedicated public funding, and restrictive GIF procedures. A revision of the regulations is being discussed that would allow private sector participation in collaboration with research institutes. Legislative decisions are expected in the second half of 2026.

What are the main challenges facing the medical marijuana industry in Poland?

Despite dynamic growth, the Polish medical marijuana market faces five significant structural barriers. According to a report by the Polish Society of Cannabis Medicine from February 2026, 73% of patients report difficulties in maintaining continuity of therapy (Polish Society of Cannabis Medicine, 2026). This is a significantly higher rate than in other chronic therapies in Poland.

The first barrier is the lack of reimbursement. The patient pays 100% of the therapy costs, which for many people amounts to 600-1500 PLN per month. This economic barrier causes a large portion of patients to dose cannabis subtherapeutically or interrupt treatment. International data shows that reimbursement increases patient adherence by 40-60% (EMCDDA, 2024).

The second barrier is the limited availability of doctors. Only about 4,200 doctors in Poland regularly issue prescriptions with „Rp.w.”, and 70% of all prescriptions are generated by the top 200 specialists (Supreme Medical Chamber, 2025). Patients often wait 4-8 weeks for an appointment or use telemedicine platforms.

Barrier 1: Shortage of trained doctors

In Poland in 2025, there were about 142,000 actively practicing doctors. Of these, less than 3% issued prescriptions for medical marijuana. The main reasons are the lack of cannabis modules in medical school curricula, professional caution, unclear dosing guidelines, and fear of GIF and NFZ inspections.

The Supreme Medical Chamber, along with the Polish Society of Cannabis Medicine, is currently preparing a training program for personnel. The first editions are planned for the third quarter of 2026. The goal is to train at least 5,000 doctors by the end of 2027. This should relieve the system from the concentration of prescriptions in a narrow group of specialists.

Barrier 2: Lack of NFZ reimbursement

Medical marijuana in 2026 is still not on the list of reimbursed drugs. The average monthly therapy cost is 600-1500 PLN, depending on the dosage and chosen strain. In comparison, in Germany, since 2017, 80% of costs have been reimbursed by the public health insurance, which has led to a market boom (Federal Ministry of Health DE, 2024).

In February 2026, the Ministry of Health announced public consultations regarding the reimbursement of medical marijuana for patients with drug-resistant epilepsy and spasticity in multiple sclerosis. A decision is expected in the fourth quarter of 2026. Reimbursement for both indications will raise the annual budget cost by an estimated 80-120 million PLN.

Barrier 3: Interruptions in the availability of products

As many as 73% of patients in a 2026 survey report that at least once a year they encountered their strain being unavailable at the pharmacy (Polish Society of Cannabis Medicine, 2026). The reason is the long logistical cycle of imports (6-12 weeks), demand fluctuations, and a small number of importers. Patients are often forced to change strains during therapy, which affects the therapeutic effect.

Barrier 4: Social and mental stigma

Despite ongoing education, 38% of Poles in a 2025 CBOS survey still associate medical marijuana with recreational marijuana (CBOS, 2025). This results in social stigma for patients who do not disclose their use of cannabis at work or to family. Some doctors also share this belief, which affects their willingness to issue prescriptions.

Barrier 5: Low market transparency

Poland does not publish public statistics on the medical marijuana market on a quarterly basis. Data comes from analyses of private industry platforms, GIF reports, and sporadically from the Ministry of Health. This lack of transparency makes planning difficult for investors, doctors, and patients. The Polish Society of Cannabis Medicine has been calling for a public registry since 2023.

How has telemedicine changed access to medical marijuana?

Telemedicine has become the main channel for accessing medical marijuana in Poland. In 2025, about 67% of all first-time prescriptions were issued via teleconsultation (Rynek Aptek, 2025). This phenomenon has revolutionized patient access to therapy, but it has also sparked a discussion about the quality of diagnosis.

Telemedicine platforms operating in Poland in 2026 include Pacjenci.com, Salveo, Hempharma, Sativa Klinik, Cannarescue, and several smaller ones. The average waiting time for a consultation is 1-3 days, and the cost of a one-time visit is 150-250 PLN. For patients from smaller towns, this is often the only option for accessing a specialist knowledgeable about cannabis therapy.

From January 2026, new rules will apply. Every teleconsultation requires a video connection (audio+video), an interview conducted in person by the doctor, and documentation in the SIM. This eliminates the practice of „prescriptions in 5 minutes”, which was loudly criticized in 2024 by the NIK and the prosecutor's office. The requirement for patient examination at least once every 6 months is now enforced.

Benefits of telemedicine for patients

The first benefit is geographical availability. Patients from smaller towns do not have to travel 100-200 km to see a specialist. The second is time; short appointment times allow for quick initiation of therapy. The third is discretion, which is important in the context of the still-present social stigma. The fourth is flexibility in appointment times, which suits working individuals.

Risks of telemedicine

The main risk is a superficial clinical assessment of the patient. In the absence of a physical examination, the doctor relies on self-reported symptoms, which can be unreliable. The second risk is a conflict of interest when the same platform generates prescriptions and sells consultations. The third is a lack of continuity of care if the patient changes platforms and doctors every few months.

The new regulation from January 2026 addresses the first risk, but the other two require further regulations. The Ministry of Health is considering introducing a requirement to assign a patient to one platform for a minimum of 12 months and a public register of doctors authorized to issue „Rp.w.” prescriptions.

In 2025, about 67% of first-time prescriptions for medical marijuana in Poland were issued via teleconsultation (Rynek Aptek, 2025). From January 2026, every such consultation requires a video connection and documentation in the Medical Information System, which introduces patient safety standards at the level of an in-person visit.

What is the market outlook for 2026-2030?

Statista and the Polish Society of Cannabis Medicine forecast the value of the Polish medical marijuana market to grow from about 110 million euros in 2025 to 280-340 million euros in 2030, with a CAGR of 20-22% (Statista, 2025). This is one of the highest growth rates in Europe and a pace similar to the markets of Germany and the Czech Republic.

Three factors will determine the actual shape of the market. First, the decision on the reimbursement of selected indications. Second, the launch of domestic production on a commercial scale. Third, the evolution of EU regulations regarding the internal trade of pharmaceutical flower. Each of these elements can accelerate or slow down growth.

From the patient's perspective, the most important factors are availability and predictability. An increase in the number of trained doctors to 5,000 by 2027 and reimbursement for two indications could double the patient base to 600-700 thousand by 2028. This means that Poland could match Germany in terms of market volume in the second half of the decade.

Optimistic scenario until 2030

With rapid reimbursement, domestic production, and an expanded list of indications, the market reaches 340 million euros, the patient base 800-900 thousand, and domestic production covers 30-40% of demand. Poland becomes a regional production hub for Central and Eastern Europe. However, this scenario requires coordinated actions from the Ministry of Health, GIF, and the private sector.

Baseline scenario until 2030

Without breakthrough reimbursement, but with increasing access to doctors and stable imports, the market reaches 280 million euros, the patient base 600 thousand. Domestic production remains marginal (5-10% of demand). Poland maintains its position as the second market in the EU by volume, but Germany strengthens its advantage.

Conservative scenario until 2030

With tightened telemedicine regulations and no reimbursement, the market grows more slowly, reaching 200 million euros, with a patient base of 450 thousand. The growth is mainly due to the exchange of opioid patients for cannabis patients, rather than market expansion. Domestic production remains in the pilot phase. Foreign investors are shifting capital to the Czech Republic and Germany.

What could change the industry landscape?

Breakthrough events could include: the introduction of domestic production under GMP standards (planned for 2027-2028), reimbursement for drug-resistant epilepsy and MS (possible Q4 2026), reform of prescription issuance rights (expansion beyond primary care doctors), and harmonization of EU regulations regarding the internal trade of flower (expected 2027-2029).

What does the distribution chain of medical marijuana look like in Poland?

The distribution chain of medical marijuana in Poland in 2026 includes five links: foreign producer, importer, pharmaceutical wholesaler, pharmacy, and patient. Each stage requires a GIF permit and GMP documentation, which constitutes 12-15% of the final product cost (Chief Pharmaceutical Inspectorate, 2025). The system is secure but slows down turnover.

The foreign producer must have an EU-GMP certificate, which is the European standard for pharmaceutical manufacturing. Without this certificate, the raw material will not be allowed for trade in Poland. The largest producers are Canadian giants like Aurora Cannabis, Tilray, Aphria, German Bionorica, and Portuguese Tilray Portugal. Each has a dedicated importer-partner in Poland.

The importer receives a GIF permit and acts as the first link in the Polish distribution system. In 2025, there were 11 such importers operating in Poland, with the top 3 handling 64% of the market volume. The importer supplies raw material to pharmaceutical wholesalers, which in turn supply pharmacies that have a GIF permit for the trade of narcotic substances.

Pharmacies authorized to dispense medical marijuana

In Poland in 2026, about 4,800 pharmacies out of a total of 13,700 (35%) have a GIF permit for the trade in narcotic drugs. Their geographical distribution is uneven: the highest concentration is in large cities, the lowest in rural areas. A patient from a small town often has to travel 30-60 km to the nearest pharmacy that fills „Rp.w.” prescriptions.

Pharmacies must maintain a separate record of the trade in narcotic substances and store products in a safe compliant with GIF requirements. These technical requirements and the cost of licensing limit the number of pharmacies willing to engage in trade. The Polish Society of Cannabis Medicine calls for simplifying procedures to increase geographical availability.

Margin of each link in the chain

The foreign producer receives 35-45% of the final price, the importer 8-12%, the wholesaler 5-8%, the pharmacy 18-25%, and taxes and excise 10-15%. The high margin of pharmacies results from compliance costs (safe, record-keeping, pharmacist training), not from pure profitability. The scale of each pharmacy is small, averaging 80-150 prescriptions per month.

Can the market be simplified? Experts from the Polish Society of Cannabis Medicine propose shortening the chain by allowing direct contracts between pharmacies and importers (bypassing wholesalers), which would reduce the price for patients by 8-12%. The decision rests with the Ministry of Health and GIF and is being discussed as part of the 2026-2027 reforms.

What does the medical marijuana industry look like in other EU countries?

Germany is the largest medical marijuana market in the EU, with 350,000 patients and a market value of about 480 million euros in 2025 (Federal Ministry of Health DE, 2024). The key is the reimbursement model of 80% by public insurers, introduced in 2017. Germany also legalized home cultivation for adults in April 2024.

The Czech Republic employs a similar model to Poland's, but with a key difference. Since 2020, there has been domestic production controlled by SUKL (the Czech equivalent of GIF), conducted by several private companies under state license. This has allowed the price of flower to drop by 40% compared to imports and increased availability for patients (SUKL, 2024).

Portugal is the largest European producer of medical marijuana in 2026. Tilray Portugal, Holigen, and several smaller companies cultivate cannabis under GACP/GMP standards on an area of about 220 ha. Most of the production is exported to Germany, the UK, Poland, and Italy. The patient market in Portugal remains small (about 12,000 patients).

What can Poland learn from its neighbors?

First, the German model shows that reimbursement fundamentally changes the size of the market. Second, the Czech model proves that domestic production is possible even with conservative legislation. Third, the Portuguese model indicates that export can be a strong economic driver. Poland has the opportunity to combine these elements if the reforms from the Ministry of Health and GIF progress.

Poland's position in the EU in 2026

Poland is the second consumer market in the EU by volume of flower (22 tons in 2025) after Germany (38 tons). In terms of monetary value, Poland ranks third, after Germany and the UK (which is no longer formally in the EU). In terms of annual growth, Poland is the leader, with a CAGR of 65% in 2024-2025 (Statista, 2025).

What are the prospects for domestic production of medical marijuana?

Domestic production of medical marijuana in Poland in 2026 is less than 0.1% of the annual demand estimated at 22 tons. The first pilot plantation of the Institute of Natural Fibers in Poznań covers 0.3 ha, and the first harvest is planned for the second quarter of 2026 (IWNiRZ, 2025). This is the beginning, but far from commercial scale.

Barriers to the development of domestic production primarily include investment costs. Building a GMP facility of 1 ha under cover requires 40-80 million PLN in capital, plus two years to obtain all permits. Without public support (grants, credit guarantees), research institutions lack funding, and the private sector has limited rights.

The second barrier is the ambiguity of the legal model for public-private cooperation. The 2022 Act formally allows institutes to conduct cultivation but does not specify the rules for partnerships with commercial companies. GIF has historically blocked most such initiatives. Ministerial consultations in 2026 aim to clarify this issue.

The example of the Czech Republic as a model

The Czech Republic started domestic production in 2020 by establishing SUKL-licensed private companies. Four companies obtained licenses, and the first harvests satisfied 30% of the domestic market as early as 2022 (SUKL, 2024). The price of flower dropped by 40%, and availability for patients increased. This is real evidence that domestic production is achievable within 3-5 years of legislative decision.

Benefits of domestic production for Poland

The first benefit is the security of the supply chain. Lack of dependence on imports eliminates geopolitical and logistical risks. The second is a price reduction for patients, estimated at 30-40% with a market coverage of about 30%. The third is new jobs, about 2-3 thousand in the cultivation and processing sector. The fourth is export potential to EU countries without their own production.

What is the role of education in the development of the industry?

Education of medical personnel is the foundation for the sustainable development of the industry. Only 9% of graduates from Polish medical universities in 2025 had any module on cannabinoids in their curriculum (Supreme Medical Chamber, 2025). This is a deficit that the Polish Society of Cannabis Medicine and NIL plan to address in 2026-2028.

Patients also need reliable education. According to a survey by the Polish Society of Cannabis Medicine from 2026, 64% of new patients learn about cannabis therapy from social media, and only 22% from their primary care doctor. This translates into unrealistic expectations, the risk of subtherapeutic dosing, and low therapeutic adherence.

The third educational pillar is social education. A CBOS survey from 2025 showed that 38% of Poles associate medical marijuana with recreational marijuana, and 47% are unaware of the legal basis for its legality (CBOS, 2025). Information campaigns by the Ministry of Health, NIL, and patient organizations can gradually change this social perception.

Educational initiatives 2026-2027

NIL and PTMK are preparing a joint training program for doctors “Cannabinoids in Clinical Practice”. The first editions are planned for the third quarter of 2026. The goal is to train 5,000 doctors by the end of 2027, which is more than a tenfold increase compared to the current state. The training will cover indications, dosing, interactions, and patient monitoring.

For patients

The Polish Society of Cannabis Medicine has been publishing guides for patients on starting therapy since 2024. In 2026, the first Polish mobile application for tracking dosing and symptoms is planned, developed in collaboration with the Medical University of Warsaw. The application aims to assist in communication with the doctor and optimize therapy.

Frequently asked questions

Is medical marijuana legal in Poland in 2026?

Yes. Medical marijuana has been legal in Poland since November 1, 2017, under the amendment to the Act on Counteracting Drug Addiction (Dz.U. 2017 poz. 1458). To obtain the preparation, the patient needs a prescription with the entry „Rp.w.” issued by a doctor. In 2026, the number of registered patients exceeded 300,000 (Chief Pharmaceutical Inspectorate, 2025).

How many patients use medical marijuana in Poland?

According to GIF and Ministry of Health data, in 2025, over 1.4 million prescriptions for hemp flower were filled in Poland, corresponding to about 300-340 thousand unique patients (Rynek Aptek, 2025). In comparison, in 2018, only 1,900 prescriptions were filled. The growth was the fastest in the EU, and the patient base is growing by about 60% annually.

Where does the medical marijuana sold in Poland come from?

100% of the pharmaceutical raw material used in Poland comes from imports. The largest suppliers are Canada (about 55% of the volume), Germany (18%), Portugal (12%), North Macedonia, and Australia (Polish Society of Cannabis Medicine, 2025). Domestic production remains in the pilot phase, and the Institute of Natural Fibers in Poznań is conducting the first plantations under GACP standards.

What conditions qualify for treatment with medical marijuana?

A doctor can issue a prescription for, among others, chronic pain resistant to treatment, drug-resistant epilepsy, multiple sclerosis, nausea after chemotherapy, anorexia in the course of HIV, Tourette's syndrome, and spasticity (Ministry of Health, 2024). The decision is individual, and the indications are not closed by law. The doctor assesses the benefits and risks of therapy.

What regulatory changes came into effect in 2025 and 2026?

As of July 1, 2025, the Ministry of Health regulation limiting the maximum amount of flower prescribed to 60 g per prescription and requiring patient examination at least once every 6 months is in effect. From January 2026, a doctor issuing an e-prescription via teleconsultation must conduct an audiovisual interview and record the visit number in the SIM (Ministry of Health, 2026).

Is medical marijuana reimbursed by NFZ?

No. Medical marijuana in Poland in 2026 is not on the list of reimbursed drugs. The full cost is borne by the patient. The average price of 1 gram of flower in pharmacies is 55-75 PLN, and the monthly cost of therapy is usually 600-1500 PLN (Rynek Aptek, 2025). Public consultations regarding the reimbursement of selected indications have been ongoing since February 2026.

How many doctors in Poland issue prescriptions for medical marijuana?

In 2025, prescriptions with „Rp.w.” were issued by about 4,200 doctors, which is less than 3% of all actively practicing doctors in Poland (Supreme Medical Chamber, 2025). Nearly 70% of prescriptions are generated by the top 200 doctors, mainly from telemedicine platforms. The Supreme Medical Chamber is preparing training recommendations for the remaining specialists.

What is the outlook for the medical marijuana market in Poland until 2030?

Statista and the Polish Society of Cannabis Medicine forecast that the value of the medical marijuana market in Poland will increase from about 110 million euros in 2025 to 280-340 million euros in 2030, with a CAGR of 20-22% (Statista, 2025). Key factors include the introduction of domestic production, reimbursement for selected indications, and the development of telemedicine.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting the use of medical marijuana or other cannabis products, consult your doctor, especially if you are taking other medications, are pregnant, breastfeeding, or have psychiatric conditions. This report is for informational purposes only and is not an investment or medical advice. The CBD and CBG products described in the commercial sections come from industrial hemp Cannabis sativa L. and are legal in Poland under the Act on Counteracting Drug Addiction.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Last update: April 26, 2026